Clinical trials in Oldenburg In Holstein – page 53

840 clinical trials in Oldenburg In Holstein, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Oldenburg In Holstein at a glance

840

clinical trials

Research sites1

Quick filters

840 trials in Oldenburg In Holstein

Open in trial search

B-cell lymphoma+2

Not recruiting

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study Comparing Polatuzumab Vedotin with Rituximab, Ifosfamide, Carboplatin, and Etoposide for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:GWT-Tud GmbH

Contact Research Centre

Malignant melanoma stage IV+1

Not recruiting

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Bristol Myers Squibb International Corporation

Contact Research Centre

Multiple sclerosis+2

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug

Germany

Participants:18–64 years
Substances:Methylprednisolone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Chronic spontaneous urticaria

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug

Study on the Effectiveness and Safety of Remibrutinib Compared to Placebo and Omalizumab in Adults with Chronic Spontaneous Urticaria Uncontrolled by Antihistamines

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Omalizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Chronic graft versus host disease

Not recruiting

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Pustular psoriasis

Not recruiting

Study on Long-Term Spesolimab Treatment for Patients with Generalized Pustular Psoriasis from Previous Trials

InvestigationalNo placebo

Study on Long-Term Spesolimab Treatment for Patients with Generalized Pustular Psoriasis from Previous Trials

InvestigationalNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Spesolimab
Sponsor:LEO PHARMA A/S

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:AstraZeneca AB

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

Registered drugNo placebo

Study Comparing Orforglipron and Dapagliflozin for Adults with Type 2 Diabetes and Poor Blood Sugar Control on Metformin

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Dapagliflozin
Sponsor:Eli Lilly & Co.

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo

Study Comparing Standard Chemotherapy with CPX-351 for Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) and Intermediate or Adverse Genetics

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Universitaetsklinikum Ulm AöR

Contact Research Centre

Breast cancer+3

Not recruiting

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug

Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:AstraZeneca AB

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Crizotinib
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 504 cities in Germany

Clinical research in Oldenburg In Holstein

What the registry says about research in the country

01 Metabolic Disorders

Innovative clinical trials focusing on Type 2 Diabetes management and treatments, including studies of novel weekly insulin alternatives and oral medications for glycemic control.

Glycemic Control Studies
Insulin Alternatives Research
Cardiovascular Outcomes

Multiple studies evaluating new therapeutic approaches for better diabetes management and reducing cardiovascular risks.

02 Weight Management

Comprehensive research into obesity treatment and weight-related conditions, examining new therapeutic combinations and their effects on weight loss and associated health conditions.

Weight Loss Interventions
Obesity Medications
Comorbidity Management

Studies focusing on innovative approaches to weight management and treating obesity-related health complications.

03 Cardiovascular Health

Research examining treatments for atherosclerotic cardiovascular disease and related conditions, with emphasis on preventing major adverse cardiovascular events.

Cardiovascular Risk Reduction
Lipid Management
Preventive Therapies

Trials evaluating new medications for improving cardiovascular outcomes in high-risk patients.

04 Gastrointestinal Studies

Clinical investigations of treatments for Crohn's Disease and other digestive conditions, focusing on long-term efficacy and safety of new therapeutic approaches.

Inflammatory Bowel Disease
Long-term Treatment Outcomes
Disease Management

Studies aimed at improving quality of life for patients with chronic gastrointestinal conditions.

05 Oncology Research

Advanced studies in colorectal cancer treatment and management, including innovative approaches to Stage II and III cancer therapy.

Cancer Treatment Protocols
Disease-Free Survival
Adjuvant Therapy

Trials evaluating new treatment strategies for improving outcomes in cancer patients.

Back to Germany All countries